{
  "pmcid": "12383695",
  "sha256": "243640754e90a61f2f568dd13badbb18f2622e706717bd81e559313edc3c0e47",
  "timestamp_utc": "2025-11-09T23:35:39.451881+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 14.531389558232934,
    "reading_ease": 20.446240963855445,
    "word_count": 249
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial Comparing Cardiovascular Effects of Oxytocin and Carbetocin during Cesarean Section"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Seventy healthy pregnant women at term (37-41 weeks) were enrolled and randomly assigned"
      },
      "Participants": {
        "score": 2,
        "evidence": "Seventy healthy pregnant women at term (37-41 weeks) were enrolled"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomly assigned to receive either 5 IU of intravenous oxytocin (OXY group, n=34) or 100 µg of intravenous carbetocin (CARBE group, n=36)"
      },
      "Objective": {
        "score": 1,
        "evidence": "This randomised controlled trial aimed to evaluate the cardiovascular effects of oxytocin and carbetocin"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the incidence of ST-segment changes, measured intraoperatively"
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "Randomisation was based on the day of the month, and allocation was not concealed"
      },
      "Blinding": {
        "score": 1,
        "evidence": "Blinding was not implemented for patients or clinicians"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "OXY group, n=34 or 100 µg of intravenous carbetocin (CARBE group, n=36)"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "The analysis was conducted on a per-protocol basis"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "The effect size for ST-segment changes was not significant (p > 0.05)"
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse cardiovascular events were reported in either group"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not provided"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not specified"
      }
    },
    "total_score": 16,
    "max_score": 25
  }
}